Q1 Earnings Estimate for ASMB Issued By HC Wainwright

Key Points

• HC Wainwright projects Q1 2027 EPS of ($0.16) for Assembly Biosciences, rates the stock Buy with a $50 price target, and provides multi-quarter and FY2030 EPS forecasts (Q2 -$1.13, Q3 -$1.10, Q4 $1.67, FY2030 $3.23).
• On March 19 the company reported a surprising beat with $2.48 EPS and $42.47M revenue—well above estimates—despite a negative net margin (-8.47%) and negative return on equity (-5.63%).
• MarketBeat shows a consensus of Moderate Buy (five Buys, one Hold, one Sell) with a $41.75 average target, and roughly 19.9% of shares held by institutions including Farallon, RA Capital and Janus Henderson.

Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings estimates for Assembly Biosciences in a report issued on Thursday, March 26th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will earn ($0.16) per share for the quarter. HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences' Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($1.10) EPS, Q4 2027 earnings at $1.67 EPS and FY2030 earnings at $3.23 EPS.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $2.99. The business had revenue of $42.47 million during the quarter, compared to the consensus estimate of $7.42 million. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%.

A number of other analysts have also recently commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Wall Street Zen upgraded Assembly Biosciences from a "hold" rating to a "buy" rating in a research note on Saturday, March 21st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $41.75.

Assembly Biosciences Price Performance

ASMB stock opened at $28.87 on Friday. The company has a market cap of $457.88 million, a P/E ratio of -39.01 and a beta of 1.11. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $39.71. The stock's fifty day moving average price is $27.96 and its 200-day moving average price is $29.71.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of ASMB. Farallon Capital Management LLC purchased a new stake in shares of Assembly Biosciences during the third quarter worth about $31,426,000. RA Capital Management L.P. purchased a new position in Assembly Biosciences in the 3rd quarter worth approximately $26,122,000. Commodore Capital LP purchased a new position in Assembly Biosciences in the 3rd quarter worth approximately $25,600,000. Janus Henderson Group PLC lifted its holdings in Assembly Biosciences by 11.3% in the 4th quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company's stock worth $28,540,000 after purchasing an additional 85,299 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP bought a new position in Assembly Biosciences in the 4th quarter worth approximately $22,625,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.